T
Tetraphase Pharmaceuticals
Antibiotics to treat multi-drug resistant bacterial infections
About Tetraphase Pharmaceuticals
Tetraphase Pharmaceuticals is dedicated to addressing one of the most critical threats to global health: antibiotic resistance. The company specializes in the development of novel antibiotics aimed at treating infections caused by multidrug-resistant (MDR) bacteria. Utilizing proprietary chemistry technology, Tetraphase is creating multiple tetracycline-based antibiotics that show promise against some of the most challenging MDR bacteria. The company's mission is to make these innovative antibiotics accessible to all patients who need them, thereby potentially changing the course of antibiotic resistance for millions at risk.
Tetraphase operates in the pharmaceutical and biotechnology market, primarily serving healthcare providers, hospitals, and patients who are in dire need of effective treatments against resistant bacterial infections. The business model revolves around research and development (R&D) of new antibiotic drugs, followed by clinical trials, regulatory approvals, and eventual commercialization. Revenue is generated through the sale of these antibiotics, as well as potential out-licensing agreements for their pipeline products.
Source: Dealroom company dataAt a glance
- Status
- Acquired
- Founded
- 2006
- Headquarters
- Watertown, United States
- Employees
- 13
- Open positions
- None listed
- Dealroom signal
- 70.8/100
- Industry
- Health
- Sub-industry
- Pharmaceutical, BioTechnology
- Sector
- Biotech & Life Sciences, Risk Management, Biotechnology, Spinout, Biotech and Pharma, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- b2c
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| ACQUISITIONOther financing | Jul 2020 | $43M | $43M | La jolla Pharmaceutical | — |
| ACQUISITIONOther financing | Mar 2020 | $14M | $14M | Talphera | ↗ |
Financials
Revenue, earnings and other financial measures where available. Years marked “E” are estimates.
Growth signals
Latest recorded traffic for Tetraphase Pharmaceuticals is 240 monthly website visits, up 500% over the last three months. Tetraphase Pharmaceuticals's team declined 48% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed1 investor entered at this stage
CARB-X
Series A4 investors entered at this stage
- MPMediphase Venture Partners
Skyline Ventures
Flagship Pioneering
F-Prime
Series B and later2 investors entered at this stage
Excel Venture Management- CCCMEA Capital
Other known investors8 additional known investors
Harvard University
La jolla Pharmaceutical
Talphera- BCBay City Capital
CB Health Ventures
Eight Roads Ventures- FVFidelity Ventures
US Biomedical Advanced Research and Development Authority
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Tetraphase Pharmaceuticals on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Tetraphase Pharmaceuticals’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.